Argent BioPharma Files U.S. Provisional Patent for NanoBodies Platform Targeting Septic Shock

Argent Biopharma ( (AU:RGT) ) has provided an announcement.

Argent BioPharma has filed a U.S. provisional patent application for its NanoBodies platform, securing priority protection for proprietary peptide targets and nanobody constructs aimed at vascular and peptide-mediated signalling in septic shock and systemic inflammatory disorders. The programme, which will be evaluated in a cecal ligation and perforation septic shock model, is intended to work upstream of cytokine activation and complements CimetrA’s cytokine-modulating mechanism, broadening the company’s neuro-immune strategy and strengthening its long-term U.S.-centred intellectual property position in immune and inflammatory markets.

By expanding its immune-modulatory portfolio beyond cytokine regulation into upstream signalling control, Argent BioPharma is deepening its scientific differentiation in acute inflammatory conditions such as septic shock. Management highlights that the NanoBodies initiative enhances internal R&D capabilities, reinforces the structural depth of the pipeline, and may provide additional therapeutic leverage in addressing complex vascular and immune pathways relevant to severe systemic inflammation.

The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.

More about Argent Biopharma

Argent BioPharma Ltd is a revenue-generating, clinical-stage biopharmaceutical company focused on nano-engineered therapeutics for neurological and immune-mediated disorders. Its lead assets, CannEpil for drug-resistant epilepsy and CimetrA for inflammatory conditions, leverage proprietary nano-delivery technologies and vertically integrated EU-GMP manufacturing to target central nervous system and systemic inflammatory diseases with high unmet need.

Average Trading Volume: 184,217

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$4.65M

See more data about RGT stock on TipRanks’ Stock Analysis page.